Theriva™ Biologics Reports First Quarter 2025 Operational Highlights and Financial Results
- VCN-01 Achieves Primary Efficacy and Safety Endpoints for Pancreatic Ductal Adenocarcinoma in VIRAGE Phase 2b Clinical Trial - -...
Staff
Silo Pharma Advances PTSD Drug SPC-15 Toward First-in-Human Trial with Key Safety Study Initiated at Frontage Laboratories
Clear Regulatory Path to Clinical Trials for Intranasal PTSD Therapy Targeting Multi-Billion-Dollar MarketSARASOTA, FL, May 14, 2025 (GLOBE NEWSWIRE) --...
Neuronetics Launches First Inaugural National TMS Therapy Awareness Day During Mental Health Awareness Month
New national awareness day will foster greater understanding of transcranial magnetic stimulation (TMS) treatment The company will celebrate on social...
Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway
Newly granted patent is part of the expanding intellectual property portfolio directed to: -generating novel and selective Wnt surrogate molecules...
Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations
New entity, ErnexaTX2, reflects progress toward clinical readinessCAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing...
UPDATE — Abeona Therapeutics® and Lurie Children’s Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder
- ZEVASKYN, the first and only cell-based gene therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB), now commercially available...
IO Biotech Reports First Quarter 2025 Financial Results and Business Highlights
Primary endpoint of pivotal Phase 3 trial (IOB-013/KN-D18) of lead investigational therapeutic cancer vaccine in patients with advanced melanoma still...
Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences
BRISBANE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to...
Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update
ATRN-119, our ATR inhibitor, exhibits early evidence of single agent, anti-tumor activity and is progressing toward the recommended Phase 2...
Indaptus Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage...
BetterLife Pharma Provides Scientific Update of Mechanism of Action of BETR-001 in Treatment of Psychiatric Disorders
VANCOUVER, British Columbia, May 14, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB...
aTyr Pharma Advances ATYR0101 to IND Candidate Stage for Pulmonary Fibrosis
Preclinical data demonstrate ATYR0101’s unique anti-fibrotic mechanism through interaction with LTBP-1. ATYR0101 to be showcased in oral presentation at the...
3Daughters Selects Connect Labs by Wexford – Baltimore for New Corporate Headquarters
Access to Wexford Knowledge Community Platform Supports Creation of a Women’s Health Science HubPresence within UMB BioPark Ecosystem and Provides...
Revolution Medicines Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating Daraxonrasib in Previously Treated Patients with RAS Mutant Non-Small Cell Lung Cancer
REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing...
INmune Bio Inc. Announces Attendance at the 2025 RBC Capital Markets Global Healthcare Conference
BOCA RATON, Fla., May 14, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage biotechnology company targeting...
Targeted Genomics Announces Commercial Collaboration with OraSure Technologies for Direct to Consumer (DTC) Celiac Genetic Testing
IRVINE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Targeted Genomics LLC, developer of GlutenID, the first and only U.S. Food...
FDA and Cingulate Aligned with Filing Requirements for New Drug Application for Lead ADHD Asset CTx-1301
Pre-NDA Minutes from April 2, 2025, Meeting Received NDA Submission Planned this Summer KANSAS CITY, Kan., May 14, 2025 (GLOBE...
Channel Therapeutics Announces Positive Efficacy Results for the Treatment of Eye Pain Using its NaV1.7 Inhibitor in Multiple Preclinical In Vivo Models
Global Chronic Ocular Pain Market Valued at US$ 7.2 Billion in 2023 and Is Projected To Reach US$ 12.44 Billion by...
Hydreight Technologies to Present at Maxim Group’s 2025 Virtual Tech Conference & the CEM Bermuda Capital Event
VANCOUVER, British Columbia and LAS VEGAS, May 14, 2025 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (“Hydreight” or the “Company”) (TSXV:...
Daxor Announces Duke University Study on Blood Volume Analysis in Heart Failure Published in American Heart Journal
Published Research Demonstrates the Value of BVA in Meeting Key Goal of Identifying Anemia in Heart Failure Patients Oak Ridge,...